First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 234 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 Opinion: “We’ve been pushing for change for 20 years. We’re not... January 24, 2022 pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... February 16, 2021 Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... September 11, 2020 Load more HOT NEWS Aggressive Prostate Cancer Subtype More Common Than Expected ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy EMA Recommends Extension of Therapeutic Indications for Selinexor Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for...
